Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2005, for Bioanalytical Systems, Inc. (Note: The request metadata lists "Inotiv, Inc.", but the filing text explicitly identifies the registrant as Bioanalytical Systems, Inc.). The company operates in two segments: Research Services (contract laboratory and analytical support) and Research Products (scientific instruments and consumables). The company's performance is heavily dependent on pharmaceutical and biotech industry drug discovery efforts.
Key Financial Metrics
| Metric | Q1 2006 (Ended Dec 31, 2005) | Q1 2005 (Ended Dec 31, 2004) |
|---|---|---|
| Total Revenue | $9,844,000 | $9,694,000 |
| Gross Profit | $3,146,000 (31.9% margin) | $3,627,000 (37.4% margin) |
| Operating Income (Loss) | $(913,000) | $905,000 |
| Net Income (Loss) | $(716,000) | $404,000 |
| Diluted EPS | $(0.15) | $0.08 |
| Cash and Equivalents | $680,000 | $1,394,000 (End of period) |
| Operating Cash Flow | $(339,000) used | $(594,000) used |
| Total Debt (Current + Long-Term) | $11,218,000 | N/A (Balance sheet comparison only) |
| Available Credit Facility | $2,629,000 | N/A |
Material Changes vs. Prior Period
- Revenue Mix Shift: Total revenue increased 2% ($150k), but the composition changed significantly. Service revenue declined 34% ($1.6M) due to a delayed project in West Lafayette, partially offset by 36% growth in the Baltimore clinical unit and 85% growth in the Evansville toxicology unit. Product revenue declined 4% ($99k).
- Margin Compression: Gross margin fell from 37.4% to 31.9%. Cost of service revenue as a percentage of revenue rose to 77.8% from 71.5% due to underutilized fixed capacity (personnel, facilities) in the face of lower service volumes.
- Operating Expenses Surge: Total operating expenses increased 49% ($1.3M). General and Administrative (G&A) expenses rose 50% to $2.887M, driven by a sales/leaseback transaction in Baltimore, increased personnel costs, and the new adoption of stock-based compensation expense ($67k) under FAS 123(R).
- Profitability Reversal: The company swung from a net income of $404k to a net loss of $716k, primarily due to the operating loss caused by margin compression and higher operating expenses.
Guidance, Outlook, Risks, and Unusual Items
- Capital Expenditures: Management expects total capital expenditures for the fiscal year to range between $2,000k and $2,500k, with $1,500k financed via capital leases.
- Liquidity and Covenants: The company holds $680k in cash and has $2,629k available under a $6,000k revolving credit facility. However, the company was not in compliance with its fixed charge coverage ratio covenant due to the quarterly loss. A waiver was obtained from the bank.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of December 31, 2005. This is due to the implementation of a new ERP system across five locations, which caused delays in auditing and reporting financial data for the prior fiscal year.
- Market Risk: The company is exposed to interest rate fluctuations on its floating-rate debt and foreign currency exchange rates (approx. 70% of cash is in the U.K.), though management estimates a 10% adverse change would not be material.
Investor Verification Checklist
- Covenant Compliance: Verify the status of the waiver obtained for the fixed charge coverage ratio and the likelihood of future compliance.
- ERP Implementation: Assess the timeline for fully stabilizing the new accounting system and the potential for further reporting delays or restatements.
- Project Pipeline: Confirm the status of the delayed West Lafayette project and the sustainability of growth in the Baltimore and Evansville units.
- Debt Structure: Review the terms of the $6,000k revolving credit facility, specifically the borrowing base limitations and the impact of the $2,000k letter of credit.
- Stock Compensation Impact: Monitor the ongoing impact of FAS 123(R) adoption on future operating expenses and net income.